Apmonia Therapeutics
- Biotech or pharma, therapeutic R&D
Apmonia Tx is a leading French company offering a breakthrough technology by attacking extracellular matrix proteins as a new oncology class. At the convergence of several scientific and technological advances, Apmonia Tx is developing both a unique in silico discovery platform [powered by virtual screening and AI], and a portfolio of drug candidates.
Flagship product is a tumor microenvironment modulator that blocks the interaction between thrombospondin-1 (TSP-1) and CD47 receptors. It is ready to enter Phase 1/2a trial in several advanced solid tumors (CTA/IND-ready).
)
)
)
){kind=logo}
)
){kind=logo}
){kind=logo}